Physician profile
James S Morgan
NPI 1619130390
$3,089.67
in general payments reported to CMS, 2019-2025
46 companies · $670 in 2025
The $670 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $216 · 2021: $404 · 2022: $266 · 2023: $347 · 2024: $873 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806 · Education: $83.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.63 |
| Education | $83.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $362.38 | 2019-2025 | |
| Celgene Corporation | $234.60 | 2021-2024 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $210.80 | 2020-2025 | Tagrisso, Lynparza, Enhertu |
| Amgen INC. | $205.05 | 2019-2024 | |
| Janssen Biotech, INC. | $171.19 | 2021-2025 | Tecvayli, Darzalex, Rybrevant |
| Pfizer INC. | $166.75 | 2020-2025 | |
| Astellas Pharma US INC | $133.29 | 2021-2025 | Vyloy |
| Merck Sharp & Dohme LLC | $126.75 | 2019-2025 | Keytruda, Welireg |
| Shire North American Group INC | $112.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $111.05 | 2020-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $100.96 | 2021-2025 | Injectafer, Enhertu |
| Genzyme Corporation | $92.16 | 2019-2025 | |
| Kite Pharma, INC. | $65.42 | 2020-2025 | Yescarta |
| Foundation Medicine, INC. | $61.09 | 2019-2023 | Foundationone Liquid Cdx |
| Mirati Therapeutics, INC. | $60.08 | 2023 | Krazati |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.